Rapport Therapeutics, Inc
Financing
Shares on issue
48.1M
From 36.6M in June 2024
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-03-10. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since.
$110.0M
Leerink Partners, agreement of 2026-01-07. No at-the-market sales on file.
Warrants
No warrant count on file.
Cash
13.1 quarters
$395.0M cash on hand.
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-10-30 | Private placement | 1,428,571 | not available | $30.0M | 8-K ↗ |
| 2026-10-28 | Public offering incl. 1.19M pre-funded | 9,523,810 | $21.00 | $200.0M | 424B5 ↗ |
| 2025-09-09 | Public offering | 9,615,385 | $26.00 | $250.0M | 424B5 ↗ |
| 2024-06-06 | Public offering | 8,000,000 | $17.00 | not available | 424B4 ↗ |
Also on file: $150.0M convertible notes, 2026-10-28 424B5 ↗ · $150.0M convertible notes, 2026-10-28 8-K ↗